APTO · Aptose Biosciences Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $11.34M | $15.10M | $33.27M | $28.09M | $45.98M | $29.29M |
| SG&A | $13.38M | $11.15M | $15.59M | $14.51M | $19.46M | $26.48M |
| Total Operating Expenses | $24.72M | $26.26M | $52.36M | $42.60M | $65.45M | $55.77M |
| D&A | $22.0K | $32.0K | $88.0K | $120.0K | $150.0K | $152.0K |
| Operating Income | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $0 | - | - | - | - |
| Net Income | ($25.47M) | ($25.43M) | ($51.21M) | ($41.82M) | ($65.35M) | ($55.24M) |
| EPS - Basic | ($10.41) | ($36.38) | ($7.58) | ($0.73) | - | - |
| EPS - Diluted | ($10.41) | ($36.38) | ($7.58) | ($0.45) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $935.0K | $6.15M | $9.25M | $36.97M | $39.11M | $117.39M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.91M | $1.26M | $3.49M | $6.33M | $1.70M | $2.17M |
| Current Assets | $6.45M | $9.53M | $11.89M | $49.52M | $81.74M | $125.08M |
| Total Assets | $10.01M | $10.13M | $12.99M | $51.03M | $82.53M | $126.26M |
| Current Liabilities | $9.31M | $4.46M | $15.27M | $12.28M | $8.17M | $6.81M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $37.18M | $14.67M | $15.89M | $13.29M | $8.29M | $7.35M |
| Stockholders' Equity | ($27.17M) | ($4.54M) | ($2.90M) | $37.74M | $74.24M | $118.92M |
| Retained Earnings | ($566.43M) | ($540.97M) | ($515.54M) | ($464.33M) | ($422.51M) | ($357.15M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($21.99M) | ($35.98M) | ($44.59M) | ($32.32M) | ($43.30M) | ($33.89M) |
| Investing Cash Flow | $0 | $18.0K | $9.96M | $30.07M | ($35.21M) | $12.63M |
| Financing Cash Flow | $19.38M | $33.41M | $6.91M | $116.0K | $226.0K | $58.81M |
| CapEx | $0 | $5.0K | $29.0K | $24.0K | $212.0K | $79.0K |
| Free Cash Flow | ($21.99M) | ($35.98M) | ($44.62M) | ($32.35M) | ($43.52M) | ($33.97M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.86 | 1.41 | 0.87 | 0.77 | 0.67 | 0.61 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -254.4% | -251.1% | -394.2% | -82.0% | -79.2% | -43.7% |
| Return on equity | 93.7% | 559.8% | 1765.1% | -110.8% | -88.0% | -46.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.69 | 2.14 | 0.78 | 4.03 | 10.00 | 18.36 |
| Quick ratio | 0.69 | 2.14 | 0.78 | 4.03 | 10.00 | 18.36 |
| Cash ratio | 0.10 | 1.38 | 0.61 | 3.01 | 4.79 | 17.23 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -0.37 | -2.23 | -4.48 | 1.35 | 1.11 | 1.06 |
| Liabilities / Assets | 3.71 | 1.45 | 1.22 | 0.26 | 0.10 | 0.06 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - |
| Net income growth (YoY) | -0.1% | 50.3% | -22.4% | 36.0% | -18.3% | -110.2% |
| EPS growth (YoY) | 71.4% | -379.9% | -1584.4% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 38.9% | 19.4% | -37.9% | 25.7% | -28.1% | -56.8% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -498.0% | -56.6% | - | -49.2% | -37.6% | 26.6% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Aptose Biosciences Inc. against the 5 most active filers in the same SIC group.